


# PRODUCT INFORMATION



## ABBV-075

Item No. 21033

**CAS Registry No.:** 1445993-26-9  
**Formal Name:** N-[4-(2,4-difluorophenoxy)-3-(6,7-dihydro-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]-ethanesulfonamide  
**Synonym:** Mivebresib  
**MF:** C<sub>22</sub>H<sub>19</sub>F<sub>2</sub>N<sub>3</sub>O<sub>4</sub>S  
**FW:** 459.5  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 229, 297 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

ABBV-075 is supplied as a crystalline solid. A stock solution may be made by dissolving the ABBV-075 in the solvent of choice, which should be purged with an inert gas. ABBV-075 is soluble in organic solvents such as DMSO and acetonitrile. The solubility of ABBV-075 in these solvents is approximately 20 and 1 mg/ml, respectively.

### Description

ABBV-075 is a potent inhibitor of the bromodomain and extra terminal domain (BET) family of proteins that is selective for the bromodomain-containing proteins (BRD) BRD2, BRD4, and BRDT (K<sub>i</sub>s = 1-2.2 nM) over BRD3 (K<sub>i</sub> = 12.2 nM) and against a panel of 18 BRD proteins.<sup>1</sup> It inhibits BRD4 recruitment to androgen receptor-occupied gene enhancer sites leading to growth inhibition in androgen receptor-dependent prostate cancer cells.<sup>2</sup> ABBV-075 halts the cell cycle in the G<sub>1</sub> phase and induces apoptosis in prostate cancer cells as well as patient-derived acute myeloid leukemia (AML), non-Hodgkin lymphoma, and multiple myeloma cells.<sup>3</sup> It is also efficacious in many xenograft mouse models including lung and prostate cancers, AML, and multiple myeloma.<sup>1-3</sup>

### References

1. Sarthy, A., Li, L., Alpert, D.H., *et al.* Abstract 4718: ABBV-075, a novel BET family bromodomain inhibitor, represents a promising therapeutic agent for a broad spectrum of cancer indications. *Cancer Res.* **76(14 Suppl)**, (2016).
2. Faivre, E.J., Wilcox, D., Lin, X., *et al.* Exploitation of castration-resistant prostate cancer transcription factor dependencies by the novel BET inhibitor ABBV-075. *Mol. Cancer Res.* **15(1)**, 35-44 (2017).
3. Bui, M.H., Lin, X., Albert, D.H., *et al.* Preclinical characterization of BET family bromodomain inhibitor ABBV-075 suggests combination therapeutic strategies. *Cancer Res.* **77(11)**, 2976-2989 (2017).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/24/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
[WWW.CAYMANCHEM.COM](http://WWW.CAYMANCHEM.COM)